4.6 Review

Neuropathic pain: an updated grading system for research and clinical practice

期刊

PAIN
卷 157, 期 8, 页码 1599-1606

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/j.pain.0000000000000492

关键词

Neuropathic pain; Definition; Grading; Possible; Probable; Definite

资金

  1. NeuPSIG of the International Association
  2. NIGMS [NS26363]
  3. European Commission Horizon 2020 [ID633491]
  4. Nordisk Foundation [NNF14SA0006]
  5. Pfizer
  6. Genzyme
  7. Grunenthal
  8. Mundipharma
  9. EU Project [633491: DOLOR-isk]
  10. Sanofi Pasteur
  11. Medtronic
  12. Eisai
  13. Lilly
  14. Boehringer Ingelheim
  15. Astellas
  16. Desitin
  17. Teva Pharma
  18. Bayer-Schering
  19. MSD
  20. bioCSL
  21. Novo Nordisk Fonden [NNF14OC0011633] Funding Source: researchfish

向作者/读者索取更多资源

The redefinition of neuropathic pain as pain arising as a direct consequence of a lesion or disease affecting the somatosensory system, which was suggested by the International Association for the Study of Pain (IASP) Special Interest Group on Neuropathic Pain (NeuPSIG) in 2008, has been widely accepted. In contrast, the proposed grading system of possible, probable, and definite neuropathic pain from 2008 has been used to a lesser extent. Here, we report a citation analysis of the original NeuPSIG grading paper of 2008, followed by an analysis of its use by an expert panel and recommendations for an improved grading system. As of February, 2015, 608 eligible articles in Scopus cited the paper, 414 of which cited the neuropathic pain definition. Of 220 clinical studies citing the paper, 56 had used the grading system. The percentage using the grading system increased from 5% in 2009 to 30% in 2014. Obstacles to a wider use of the grading system were identified, including (1) questions about the relative significance of confirmatory tests, (2) the role of screening tools, and (3) uncertainties about what is considered a neuroanatomically plausible pain distribution. Here, we present a revised grading system with an adjusted order, better reflecting clinical practice, improvements in the specifications, and a word of caution that even the definite level of neuropathic pain does not always indicate causality. In addition, we add a table illustrating the area of pain and sensory abnormalities in common neuropathic pain conditions and propose areas for further research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据